🇺🇸 FDA
Pipeline program

SPYPBO-101 Placebo to SPY072, SPY072

SPY002-072-201

Phase 2 small_molecule active

Quick answer

SPYPBO-101 Placebo to SPY072, SPY072 for Moderately to Severely Active Rheumatologic Disease is a Phase 2 program (small_molecule) at Spyre Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Spyre Therapeutics
Indication
Moderately to Severely Active Rheumatologic Disease
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials